Carsten Thiel is a biopharmaceutical expert with over 25 years experience in the commercial pharmaceutical industry. Holding a PhD in Molecular Biology and Biochemistry, he has contributed to countless medical advancements throughout his career, particularly in the fields of oncology and rare diseases.
Throughout the lengthy span of a professional career, countless hours are spent participating in a melee of activities, problem solving within extenuating circumstances, and developing the skills needed to excel in a variety of situations. Working professionals sometimes find themselves in unfamiliar territory, requiring critical thinking skills, intuitive action, and swift judgment to navigate the uncharted waters that are often associated with professional endeavors.
Carsten Thiel, President of European Commercialization, EUSA Pharma By CorpGov Staff In recent months, the Center for Disease Control and Prevention (CDC) announced the outbreak of a public health emergency of international concern – also known as the disease labeled COVID-19, or the Coronavirus. Coronaviruses
UK and USA-based specialty drugmaker EUSA Pharma today announced the strengthening of its senior leadership… To continue reading The Pharma Letter please login, subscribe or claim a 7 day free trial subscription and access exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space.
Through an average career cycle, one can ebb and flow with the change of tides, finding themselves accidentally in various positions. With just enough sheer luck, one may even find advancement in a given field, acquiring just enough knowledge, insight, and experience required to perform all required
Local news and events from New York City, NY Patch. Latest headlines: NYC’s Most Popular Area For Homebuyers Isn’t The One You’d Expect; Presidents’ Day In NYC: What’s Open And Closed
Newly appointed President Europe of rapidly expanding global specialized pharmaceutical giant EUSA, which focuses on treatment and cure of rare diseases and oncology care, Carsten Thiel brings over twenty years of pertinent experience within the pharmaceutical sector to his new role.